Hikal Peer Comparison

NSE: HIKAL | BSE: 524735

₹218.05

₹9.25 (4.43%)

As on 29-Sep-2026IST

Market cap

₹2,689 Cr

Revenue (TTM)

₹1,735 Cr

P/E Ratio

P/B Ratio

2.3

Div. Yield

0.3 %

Edit

	Hikal	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Market cap (₹ Cr)	2,689	35,717	27,932	26,719	27,040
Revenue (₹ Cr)	1,735	3,564	9,205	1,936	1,462
Net Profit (₹ Cr)	-33.80	414.00	-371.81	288.22	387.35
Net Margin (%)	-1.93	11.23	-3.93	14.79	26.01
RoE (%)	5.49	8.38	-3.85	29.77	25.18
Price to Earnings	--	87.33	--	92.70	70.01
Price-To-Book	2.26	7.09	3.49	19.90	15.67

Income Statement (₹ Cr)

	Hikal	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Operating Revenue	1,735.00	3,564.00	9,205.28	1,935.80	1,461.80
Total Income	1,748.10	3,686.00	9,449.59	1,948.58	1,489.25
Total Expenditure	1,502.70	2,792.00	8,195.15	1,485.56	919.25
EBITDA	232.30	772.00	1,010.13	450.24	542.56
Depreciation	167.10	226.00	857.51	50.83	37.68
EBIT	65.20	546.00	152.62	399.41	504.88
Interest	59.90	217.00	342.73	40.84	3.77
Other Income	13.10	122.00	244.31	12.78	27.45
Exceptional Items	-76.20	12.00	-216.88	0.00	0.00
Profit before Tax	-57.80	463.00	-162.68	371.35	528.56
Provision for Tax	-24.00	49.00	209.13	83.14	141.21
Profit after Tax	-33.80	414.00	-371.81	288.22	387.35

	Hikal	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Shareholder's Funds	1,198.80	4,940.00	8,162.62	1,288.82	1,653.56
Minority Interest	0.00	-5.00	0.00	0.00	-1.13
Non-Current Liabilities	487.70	1,712.00	5,044.14	202.03	42.40
Current Liabilities	678.90	1,622.00	4,758.28	835.87	230.82
Total Liabilities	2,365.40	8,578.00	17,723.32	2,326.71	1,983.96

	Hikal	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Non-Current Assets	1,374.30	5,343.00	10,211.52	519.60	1,026.85
Current Assets	884.10	2,606.00	7,191.66	1,681.81	881.27
Total Assets	2,365.40	8,578.00	17,723.32	2,326.71	1,983.96
Total Debt*	680.60	2,125.00	5,495.48	259.37	26.49
Net Current Assets	205.20	984.00	2,433.38	845.94	650.46
Contingent Liabilities	64.10	768.26	95.72	19.09	17.25

	Hikal	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Cash From Operating Activities	302.00	390.00	1,652.60	205.05	292.17
Cash Flow from Investing Activities	-145.30	-241.00	-826.03	-409.72	-265.94
Cash from Financing Activities	-160.10	-54.00	-38.98	283.07	4.10
Net Cash Inflow / Outflow	-3.40	95.00	787.59	78.39	30.33

	Hikal	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
ROCE (%)	-0.83	6.79	1.24	29.22	32.42
ROE (%)	5.49	8.38	-3.85	29.77	25.18
ROA (%)	-1.38	4.94	-2.21	24.77	21.93
EBIT Margin (%)	3.76	15.32	1.66	20.63	34.54
Net Margin (%)	-1.93	11.23	-3.93	14.79	26.01
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Hikal	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Revenue Growth (%)	-5.37	18.37	0.78	46.65	40.90
EBIT Growth (%)	-57.52	252.26	-70.53	62.13	124.50
Net Profit Growth (%)	-153.40	377.85	-1,383.43	89.49	104.15
EPS Growth (%)	3.69	1,001.33	-484.84	78.60	42.32
Book Value Growth (%)	-5.03	13.47	0.33	144.31	26.03

	Hikal	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Price / Earnings	40.97	89.63	-89.26	91.28	70.01
Price / Book Value	2.26	7.09	3.49	19.90	15.67
Dividend Yield (%)	0.28	0.00	0.00	0.09	0.08
EV/EBITDA	14.45	48.16	31.75	59.15	49.47
Market Cap (₹ Cr)	1,816.04	19,071.62	18,108.89	12,753.19	20,944.75

	Hikal	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Debt to Equity	0.31	0.31	0.53	0.11	0.02
Short term debt to equity ratio	0.15	0.09	0.09	0.05	0.02
Current Ratio	1.30	1.61	1.51	2.01	3.82
Quick Ratio	0.77	1.06	0.87	1.14	2.82
Interest Coverage	0.04	3.13	0.53	10.09	141.16

	Hikal	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Debtors to sales (%)	25.45	16.50	23.44	26.28	24.80
Asset Turnover	0.71	0.43	0.55	1.66	0.83
Receivable days	102.73	58.75	78.20	40.13	88.98
Inventory Days	73.81	75.82	93.30	60.29	56.04
Payable days	136.71	186.21	226.14	232.47	99.95
Cash Conversion Cycle	39.82	-51.64	-54.64	-132.04	45.07

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.